Aurinia Pharmaceuticals Inc. (AUPH)
Company Info
Highlights
$1.10B
$0.26
30.69
$247.30M
$218.23M
$54.34M
$5.15 - $10.67
$10.00
8.99%
8.77
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Aurinia Pharmaceuticals Inc. (AUPH) returned -11.02% year-to-date (YTD) and 54.84% over the past 12 months. Over the past 10 years, AUPH returned 8.54% annually, underperforming the S&P 500 benchmark at 10.84%.
AUPH
-11.02%
-1.60%
-9.72%
54.84%
-12.51%
-12.82%
8.54%
^GSPC (Benchmark)
0.52%
6.32%
-1.44%
12.25%
12.45%
14.20%
10.84%
Monthly Returns
The table below presents the monthly returns of AUPH, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -11.47% | 0.00% | 1.13% | 2.49% | -3.03% | -11.02% | |||||||
| 2024 | -16.13% | -24.14% | -12.41% | 1.60% | 6.48% | 5.35% | 2.98% | 15.82% | 7.64% | -1.64% | 22.88% | 1.35% | -0.11% |
| 2023 | 109.49% | 0.44% | 20.57% | 2.65% | -20.36% | 8.04% | 19.63% | -21.68% | -14.33% | -5.53% | 17.71% | 4.05% | 108.10% |
| 2022 | -27.15% | -26.17% | 0.65% | -16.88% | 9.62% | -10.90% | -18.61% | -10.02% | 2.17% | 8.11% | -36.90% | -15.79% | -81.11% |
| 2021 | 20.82% | -16.22% | -7.25% | 2.19% | 9.42% | -10.74% | 4.63% | 20.06% | 35.93% | 49.48% | -43.05% | 21.39% | 65.37% |
| 2020 | -9.67% | -4.37% | -17.09% | 18.81% | -7.95% | 2.39% | -13.05% | 4.95% | -0.67% | 6.45% | -3.06% | -9.01% | -31.74% |
| 2019 | -7.62% | 7.14% | -3.70% | -5.08% | 5.02% | 1.54% | -3.34% | -9.75% | -6.97% | -8.99% | 63.37% | 155.16% | 197.07% |
| 2018 | 17.00% | -1.70% | -0.38% | 1.16% | 11.05% | -3.43% | -3.91% | 3.14% | 19.00% | -18.07% | 11.40% | 12.54% | 50.55% |
| 2017 | 46.67% | 15.58% | 106.18% | -4.50% | -10.98% | -1.76% | 2.94% | 2.85% | -3.39% | -6.22% | -10.20% | -14.20% | 115.71% |
| 2016 | -19.03% | 18.50% | 22.78% | 0.34% | 1.71% | -6.73% | 22.77% | -42.95% | 55.15% | 0.66% | 0.33% | -30.92% | -14.98% |
| 2015 | -7.97% | 40.30% | -7.23% | -12.39% | -8.12% | -13.96% | 22.52% | -8.11% | -16.47% | 2.82% | -13.70% | -1.98% | -32.14% |
| 2014 | 18.57% | -27.67% | 7.94% | 8.15% | 29.79% | -5.91% | -15.91% | -6.27% | 12.50% | 12.50% | -10.12% | 9.61% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 82, AUPH is among the top 18% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Aurinia Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aurinia Pharmaceuticals Inc. was 87.58%, occurring on Dec 27, 2022. The portfolio has not yet recovered.
The current Aurinia Pharmaceuticals Inc. drawdown is 75.85%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -87.58% | Nov 1, 2021 | 291 | Dec 27, 2022 | — | — | — |
| -69.79% | Dec 3, 2012 | 13 | Jun 20, 2013 | 139 | Mar 18, 2015 | 152 |
| -67.17% | Mar 24, 2015 | 208 | Jan 19, 2016 | 284 | Mar 6, 2017 | 492 |
| -63.19% | Mar 14, 2017 | 652 | Oct 14, 2019 | 37 | Dec 5, 2019 | 689 |
| -53.4% | Jan 3, 2020 | 340 | May 10, 2021 | 88 | Sep 14, 2021 | 428 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aurinia Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Aurinia Pharmaceuticals Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 60.0% positive surprise.
Valuation
The Valuation section provides an overview of how Aurinia Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for AUPH, comparing it with other companies in the Biotechnology industry. Currently, AUPH has a P/E ratio of 30.7. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for AUPH compared to other companies in the Biotechnology industry. AUPH currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AUPH relative to other companies in the Biotechnology industry. Currently, AUPH has a P/S ratio of 4.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AUPH in comparison with other companies in the Biotechnology industry. Currently, AUPH has a P/B value of 3.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |